U.S. Paper and Forestry Products Stock News

Crinetics Pharmaceuticals (CRNX) is back in focus after recent clinical trial results and FDA review acceptance for its lead acromegaly therapy candidate Paltusotine. These developments sharpen attention on the company’s rare disease pipeline. See our latest analysis for Crinetics Pharmaceuticals. Crinetics’ recent trial readouts and the FDA’s acceptance of the Paltusotine filing come after a 30 day share price return of 17.38% decline and a 1 year total shareholder return of 33.30%, which...

What PROG Holdings’ Recent Performance Signals for Investors With no single headline event setting the tone, interest in PROG Holdings (PRG) today is largely about how its recent share performance, profitability and size stack up for investors watching the diversified financials space. See our latest analysis for PROG Holdings. Recent momentum has been positive, with a 30 day share price return of 11.28% contributing to a year to date share price return of 26.32%. The 1 year total shareholder...

If you are wondering whether CoreCivic is priced attractively today, this article will walk through how its current share price stacks up against a range of valuation checks. The stock last closed at US$17.17, with recent returns of a 7.5% decline over 7 days, an 8.0% decline over 30 days, a 9.7% decline year to date and a 5.5% decline over 1 year, while the 3 year and 5 year returns stand at 75.0% and 123.9% respectively. Recent coverage of CoreCivic has focused on its role in the U.S...

If you are wondering whether Kennametal's current share price lines up with its real worth, this article will walk through what the numbers suggest and what that could mean for you. With the stock at US$40.03 and returns of 4.1% over 7 days, 16.2% over 30 days, 38.1% year to date and 85.4% over 1 year, many investors are asking whether the recent performance still leaves room for value or reflects a shift in risk perceptions. Recent company updates and industry headlines have kept attention...

Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial of VK2735, a dual GLP-1 and GIP receptor agonist for obesity. The company is advancing both injectable and oral formulations of VK2735 into late-stage clinical trials. Reduced competition following a rival's clinical setback has increased attention on Viking as a potential acquisition target. Viking Therapeutics, traded as NasdaqCM:VKTX, is drawing fresh interest after reaching full enrollment in its Phase 3...

Boise Cascade (NYSE:BCC) acquired Holden Humphrey, expanding its distribution presence in the US Northeast. The company opened a new Greenfield Distribution Center in Texas, adding capacity and reach for its Building Materials Distribution segment. Boise Cascade recorded a $6 million legal accrual related to a Lacey Act investigation tied to its distribution business. Boise Cascade is a wood products and building materials distributor that serves dealers, homebuilders, and industrial...

TransMedics Group FY 2025 earnings snapshot TransMedics Group (TMDX) closed FY 2025 with fourth quarter revenue of US$160.8 million and basic EPS of US$3.08, alongside trailing twelve month revenue of US$605.5 million and EPS of US$5.60 that frame a much larger full year earnings base. Over the past few quarters, the company has seen revenue range from US$143.5 million to US$160.8 million while quarterly EPS moved between US$0.71 and US$3.08. This gives investors a clearer read on how higher...

Vanda Pharmaceuticals (VNDA) is back on investors’ radar after the U.S. Food and Drug Administration approved BYSANTI tablets for bipolar I disorder and schizophrenia, while an earlier imsidolimab filing for generalized pustular psoriasis also progresses through review. See our latest analysis for Vanda Pharmaceuticals. The recent FDA approvals and filings have coincided with sharp share price moves, with a 37.31% 7 day share price return and 56.23% 90 day share price return, while the 1 year...

On February 17, 2026, Sana Biotechnology appointed Brian Piper, M.B.A., as Chief Financial Officer, Executive Vice President, Treasurer, and Principal Financial Officer, ending CEO Steven Harr’s tenure as acting Principal Financial Officer. The move brings a veteran finance leader with extensive public biopharma and IPO experience into Sana’s top ranks, potentially reshaping how the company approaches capital allocation and investor engagement. We’ll explore how bringing in an experienced...

Textron (NYSE:TXT) has declared a quarterly dividend to be paid to shareholders. The company has also filed a shelf registration that would allow it to issue various types of securities in the future. These moves affect both near term shareholder returns and the company’s potential options for raising capital. Textron, the parent company behind businesses in aviation, defense and industrial products, is updating its financial toolkit at the same time it is returning cash to investors. The...

Recent share performance and business snapshot Rexford Industrial Realty (REXR) has seen its share price move within a mixed range recently, with a small gain of 0.6% over the past day and roughly flat performance over the past week. Over a month, the stock shows a 5.2% decline, widening to a 10.3% decline over the past 3 months. On a 1 year view, the total return stands at a 3.5% decline, while the 3 year total return reflects a 30.2% decline. In the context of this share performance, the...

In its recently reported fiscal Q1, Griffon Corporation delivered results that exceeded expectations, advanced a new joint venture between AMES North America and Venanpri Tools to build a global hand tools and home organization platform, and continued returning cash through share repurchases and its 58th consecutive quarterly dividend. An interesting angle for investors is how Griffon is pairing portfolio reshaping through the AMES–Venanpri joint venture with ongoing buybacks and regular...

If you are wondering whether ImmunityBio's recent share price action still leaves room for value, this article walks through what the current price might be implying about the business. The stock last closed at US$9.54, with returns of 11.7% over 7 days, 53.6% over 30 days, 372.3% year to date and 218.0% over 1 year, which will naturally raise questions about growth expectations and changing risk perceptions. Recent news around ImmunityBio has focused on its position in the pharmaceuticals...

Oceaneering International, Inc. recently reported fourth-quarter 2025 sales of US$668.57 million and net income of US$177.65 million, issued 2026 earnings guidance, completed a US$160.87 million share repurchase program, and is presenting at The THRIVE Energy Conference in Houston on 26 February 2026. The combination of strong year-on-year profit growth, ongoing capital returns through buybacks, and increased investor outreach highlights how management is emphasizing both operational...

If you are wondering whether Tutor Perini’s recent share price moves still leave room for value, this breakdown is designed to help you make sense of what the current price might be offering. The stock last closed at US$86.10, with returns of 6.2% over 7 days, 11.3% over 30 days, 24.2% year to date, 272.4% over 1 year, and a very large 3 year return that is close to 10x, along with a 431.3% 5 year return. Recent news around Tutor Perini has mainly focused on its position in large...

Hasbro (HAS) has been in focus after a busy February, combining fresh product reveals at the North American International Toy Fair with new licensing deals, a dismissed shareholder lawsuit and renewed tariff headlines. See our latest analysis for Hasbro. Those Toy Fair launches, the refreshed credit facility and the quick resolution of the Magic: The Gathering lawsuit all sit against a 30 day share price return of 11.56% and a 1 year total shareholder return of 53.55%. This suggests momentum...

Abbott Laboratories (NYSE:ABT) is acquiring cancer diagnostics company Exact Sciences in a deal financed by a US$20b bond sale. The transaction marks Abbott's entry into oncology diagnostics, expanding its presence in higher growth testing and screening markets. The large bond issuance is set to reshape Abbott's capital structure and raises fresh questions about risk, return and balance sheet flexibility. Abbott Laboratories, trading at around US$114.76, is moving beyond its traditional...

CCC Intelligent Solutions Holdings (CCCS) closed FY 2025 with Q4 revenue of US$277.9 million and basic EPS of US$0.01, while trailing twelve month figures show revenue of US$1.1 billion and basic EPS of essentially breakeven at US$0.00. Over recent quarters the company has seen revenue move from US$246.5 million in Q4 2024 to US$277.9 million in Q4 2025, with quarterly EPS ranging between a loss of US$0.03 and a profit of US$0.02. For investors, the latest print puts the spotlight squarely on...

If you are looking at Comcast and wondering whether the current share price reflects its underlying value, this article will walk you through what the numbers are really saying about the stock. Comcast shares recently closed at US$30.79, with returns of 4.6% over the last 30 days, 4.2% year to date, and a 1 year return of a 2.5% decline alongside a 5 year return of a 29.2% decline. Recent headlines around Comcast have focused on its position as a major US telecom and media company, including...

If you are wondering whether Novo Nordisk’s recent share price slump has created a potential opportunity or a value trap, you are in the right place. The stock last closed at US$38.16, after declines of 22.5% over 7 days, 40.4% over 30 days, and 27.2% year to date, with a 56.5% decline over 1 year and a softer 44.6% return over 3 years compared to a 13.5% gain over 5 years. These moves come as Novo Nordisk remains in the spotlight for its role in weight management and diabetes treatments...

What Sify Technologies (SIFY) Investors Might Be Watching Now Sify Technologies (SIFY) has quietly caught investor attention after a very large 1 year total return of 238%, alongside an 81% gain over the past month and 48% over the past 3 months. See our latest analysis for Sify Technologies. With the share price now at US$16.20, Sify Technologies has moved sharply over the past year, as a very large 1 year total shareholder return contrasts with a shorter term share price pullback and...

If you are wondering whether Kosmos Energy is still attractively priced after recent moves, this article walks through what the numbers actually say about its current value. The stock last closed at US$2.09, with returns of 22.9% over the past week, 64.6% over the past month and 134.1% year to date, while the 1 year, 3 year and 5 year returns stand at 21.1% decline, 72.9% decline and 35.9% decline respectively. Recent price action has come alongside ongoing investor interest in the US energy...

CACI International (CACI) is drawing fresh investor attention after its Spectral program with the U.S. Navy reached Milestone C. This clears the way for low rate initial production and deployment of its electronic warfare technology. See our latest analysis for CACI International. Alongside the Spectral milestone and upcoming investor conference appearance, CACI’s 1-year total shareholder return of 78.22% and 5-year total shareholder return of 172.69% contrast with its recent 30-day share...

If you are wondering whether Smithfield Foods is trading at an attractive price or if the recent buzz has left it looking fully priced, this article walks through the key numbers that matter. Over the past week the stock recorded a 0.4% decline, while the 30 day return sits at 4.2%, the year to date return at 10.7%, and the 1 year return at 24.6%. This has put valuation firmly on investors' radar. Recent attention on Smithfield Foods has centered on company specific developments and sector...